PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sandoz

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

May 25, 2023

Sandoz Entered into an Agreement with Just - Evotec Biologics to Develop and Manufacture Multiple Biosimilar

Sandoz Entered into an Agreement with Just - Evotec Biologics to Develop and Manufacture Multiple Biosimilar

May 9, 2023

Sandoz’s Hyrimoz (biosimilar, adalimumab) Receives EC’s Marketing Authorization for Multiple Indications

Sandoz’s Hyrimoz (biosimilar, adalimumab) Receives EC’s Marketing Authorization for Multiple Indications

April 4, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Sandoz Reports the US FDA Acceptance of BLA for Proposed Biosimilar Denosumab

Sandoz Reports the US FDA Acceptance of BLA for Proposed Biosimilar Denosumab

February 6, 2023

Sandoz Receives EMA’s CHMP Positive Opinion of Adalimumab Biosimilar

Sandoz Receives EMA’s CHMP Positive Opinion of Adalimumab Biosimilar

January 31, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us